111 related articles for article (PubMed ID: 12455149)
1. NC 100150. (Clariscan, PEG-Ferron).
Drugs R D; 2002; 3(5):303-4. PubMed ID: 12455149
[No Abstract] [Full Text] [Related]
2. The intravascular contrast agent Clariscan (NC 100150 injection) for 3D MR coronary angiography in patients with coronary artery disease.
Klein C; Nagel E; Schnackenburg B; Bornstedt A; Schalla S; Hoffmann V; Lehning A; Fleck E
MAGMA; 2000 Nov; 11(1-2):65-7. PubMed ID: 11186991
[No Abstract] [Full Text] [Related]
3. High-resolution magnetic resonance coronary angiography of the entire heart using a new blood-pool agent, NC100150 injection: comparison with invasive x-ray angiography in pigs.
Johansson LO; Nolan MM; Taniuchi M; Fischer SE; Wickline SA; Lorenz CH
J Cardiovasc Magn Reson; 1999; 1(2):139-43. PubMed ID: 11550346
[TBL] [Abstract][Full Text] [Related]
4. Clinical evaluation of ultrasmall superparamagnetic iron oxide particles for liver imaging.
Saini S; Edelman RR; Li W; Petersein J; Hahn PF
Acad Radiol; 1996 Aug; 3 Suppl 2():S409-12. PubMed ID: 8796616
[No Abstract] [Full Text] [Related]
5. Improvement of image quality of non-invasive coronary artery imaging with magnetic resonance by the use of the intravascular contrast agent Clariscan (NC100150 injection) in patients with coronary artery disease.
Klein C; Schalla S; Schnackenburg B; Bornstedt A; Hoffmann V; Fleck E; Nagel E
J Magn Reson Imaging; 2003 Jun; 17(6):656-62. PubMed ID: 12766894
[TBL] [Abstract][Full Text] [Related]
6. Ultrasmall superparamagnetic particles of iron oxide (USPIO) MR imaging of infarcted myocardium in pigs.
Kroft LJ; Doornbos J; van der Geest RJ; van der Laarse A; van der Meulen H; de Roos A
Magn Reson Imaging; 1998 Sep; 16(7):755-63. PubMed ID: 9811141
[TBL] [Abstract][Full Text] [Related]
7. Superparamagnetic nanoparticles as blood-pool contrast agents. Contribution to MRI preclinical investigations.
Benderbous S; Bonnemain B
Radiologe; 1995 Nov; 35(11 Suppl 2):S248-52. PubMed ID: 8588030
[No Abstract] [Full Text] [Related]
8. Experimental investigation of the delivery pathway of ultrasmall superparamagnetic iron oxide to lymph nodes.
Frija G; Clément O; Le Guen O; Cuénod CA; Siauve N; Benderbous S
Acad Radiol; 1996 Aug; 3 Suppl 2():S299-300. PubMed ID: 8796586
[No Abstract] [Full Text] [Related]
9. Recent advances in iron oxide nanocrystal technology for medical imaging.
Corot C; Robert P; Idée JM; Port M
Adv Drug Deliv Rev; 2006 Dec; 58(14):1471-504. PubMed ID: 17116343
[TBL] [Abstract][Full Text] [Related]
10. Superparamagnetic particles as an oral contrast agent in abdominal magnetic resonance imaging.
Oksendal AN; Jacobsen TF; Gundersen HG; Rinck PA; Rummeny E
Invest Radiol; 1991 Nov; 26 Suppl 1():S67-70; discussion S71. PubMed ID: 1808152
[No Abstract] [Full Text] [Related]
11. [Use of ultrasmall ferric oxide (Sinerem) particles as a magnetic resonance contrast substance for imaging lymph nodal metastases in cancer of the head and neck].
Sviridov NK; Napolov IuK; Bolotova EN; Iakobs LV
Vestn Rentgenol Radiol; 2004; (3):63-4. PubMed ID: 15587888
[No Abstract] [Full Text] [Related]
12. Overview of contrast enhancement with iron oxides.
Frija G; Clément O; de Kerviler E
Invest Radiol; 1994 Jun; 29 Suppl 2():S75-7. PubMed ID: 7928276
[No Abstract] [Full Text] [Related]
13. Application of superparamagnetic iron oxide (AMI-227) for 3D phase-contrast MR angiography.
Tanimoto A; Yuasa Y; Hiramatsu K
Acad Radiol; 1998 Apr; 5 Suppl 1():S113-5. PubMed ID: 9561058
[No Abstract] [Full Text] [Related]
14. MR imaging of spatial extent of microvascular injury in reperfused ischemically injured rat myocardium: value of blood pool ultrasmall superparamagnetic particles of iron oxide.
Krombach GA; Wendland MF; Higgins CB; Saeed M
Radiology; 2002 Nov; 225(2):479-86. PubMed ID: 12409583
[TBL] [Abstract][Full Text] [Related]
15. Comparative studies on the efficacy of MRI contrast agents in MRA.
Weinmann HJ; Bauer H; Ebert W; Frenzel T; Radüchel B; Platzek J; Schmitt-Willich H
Acad Radiol; 2002 May; 9 Suppl 1():S135-6. PubMed ID: 12019849
[No Abstract] [Full Text] [Related]
16. MR lymphography: evidence of extravasation of superparamagnetic nanoparticles into the lymph.
Clement O; Rety F; Cuenod CA; Siauve N; Carnot F; Bordat C; Siche M; Frija G
Acad Radiol; 1998 Apr; 5 Suppl 1():S170-2; discussion S183-4. PubMed ID: 9561073
[No Abstract] [Full Text] [Related]
17. A physiological barrier distal to the anatomic blood-brain barrier in a model of transvascular delivery.
Muldoon LL; Pagel MA; Kroll RA; Roman-Goldstein S; Jones RS; Neuwelt EA
AJNR Am J Neuroradiol; 1999 Feb; 20(2):217-22. PubMed ID: 10094341
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the time window for Resovist-enhanced T2-weighted MRI of the liver.
Reimer P; Müller M; Marx C; Balzer T
Acad Radiol; 2002 Aug; 9 Suppl 2():S336-8. PubMed ID: 12188267
[No Abstract] [Full Text] [Related]
19. Contrast-enhanced magnetic resonance angiography in the coronary and peripheral arteries.
Saeed M; Wendland MF; Engelbrecht M; Sakuma H; Higgins CB
Acad Radiol; 1998 Apr; 5 Suppl 1():S108-12. PubMed ID: 9561057
[No Abstract] [Full Text] [Related]
20. Deep venous thrombosis and consecutive pulmonary embolism as the first sign of an ovarian cancer: MR angiography using an intravascular contrast agent (CLARISCAN).
Sandstede JJ; Krause U; Pabst T; Hoffmann V; Braun H; Kenn W; Hahn D
J Magn Reson Imaging; 2000 Sep; 12(3):497-500. PubMed ID: 10992318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
